文献速递胸部肿瘤放疗放疗物理与技术

他汀类药物治疗剂量强度与非小细胞肺癌放射心脏毒性之间的关联:NI-HEART研究结果

Association between statin therapy dose intensity and radiation cardiotoxicity in non-small cell lung cancer: Results from the NI-HEART study.
PubMed 文献 · Radiother Oncol · 2023-06-20

该研究纳入2015-2020年在一家区域中心接受根治性放疗的478例非小细胞肺癌患者,59%接受他汀治疗,88%未用药者至少有一项他汀适应证。调整患者、肿瘤、治疗、反应及心血管临床因素后,高强度(HR 0.68,95%CI 0.50-0.91,p=0.012)和中强度(HR 0.70,95%CI 0.51-0.97,p=0.033)他汀治疗与总生存改善相关,心脏事件率或分级无一致差异。

要点

  • 478例接受根治性放疗的NSCLC患者中,59%接受他汀治疗,88%未用药者至少有一项他汀适应证。
  • 调整混杂因素后,高强度他汀与总生存改善相关(HR 0.68,95%CI 0.50-0.91,p=0.012)。
  • 中强度他汀亦与总生存改善相关(HR 0.70,95%CI 0.51-0.97,p=0.033),心脏事件无一致差异。

核心结论

  • 他汀治疗与接受根治性放疗的NSCLC患者总生存改善相关,并有剂量-反应关系的证据。
  • 本研究强调该队列治疗前心血管风险评估的重要性。
  • 需进一步研究他汀治疗对接受NSCLC治疗、 incidental心脏辐射剂量较高且基线心脏风险较低的患者是否具有心脏保护作用。

研究设计与样本

  • 研究纳入2015-2020年期间在一家区域中心接受治疗的患者。
  • 检索临床记录获取基线患者、肿瘤和心脏详细信息,以及随访癌症控制和心脏事件。
  • 三名心脏病专家核实心脏事件。
  • 调取放疗计划扫描用于应用经验证的基于深度学习的自动分割。
  • 采用预设Cox回归分析,对总生存进行不同程度的调整;采用Fine和Gray回归分析心脏事件风险,考虑死亡竞争风险和心脏协变量。

主要发现

  • 478例纳入患者中,59%接受他汀治疗。
  • 未接受他汀治疗的患者中,88%至少有一项心血管指南推荐的他汀治疗适应证。
  • 总共340例患者(71%)死亡,79例患者(17%)发生心脏事件。
  • 调整患者、癌症、治疗、反应和心血管临床因素后,高强度他汀治疗与总生存改善相关(HR 0.68,95%CI 0.50-0.91,p=0.012)。
  • 调整后,中强度他汀治疗与总生存改善相关(HR 0.70,95%CI 0.51-0.97,p=0.033)。

临床怎么用

  • 原文结论指出他汀治疗与接受根治性放疗的NSCLC患者总生存改善相关,并有剂量-反应关系的证据。
  • 原文强调该队列治疗前心血管风险评估的重要性。
  • 原文建议需进一步研究他汀治疗对接受NSCLC治疗、incidental心脏辐射剂量较高且基线心脏风险较低的患者是否具有心脏保护作用。

局限性

  • 需进一步研究他汀治疗对接受NSCLC治疗、incidental心脏辐射剂量较高且基线心脏风险较低的患者是否具有心脏保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Radiation cardiotoxicity is a dose-limiting toxicity and major survivorship issue for patients with non-small cell lung cancer (NSCLC) completing curative-intent radiotherapy, however patients' cardiovascular baseline is not routinely optimised prior to treatment. In this study we examined the impact of statin therapy on overall survival and post-radiotherapy cardiac events. METHODS: Patients treated between 2015-2020 at a regional center were identified. Clinical notes were interrogated for baseline patient, tumor and cardiac details, and both follow-up cancer control and cardiac events. Three cardiologists verified cardiac events. Radiotherapy planning scans were retrieved for application of validated deep learning-based autosegmentation. Pre-specified Cox regression analyses were generated with varying degrees of adjustment for overall survival. Fine and Gray regression for the risk of cardiac events, accounting for the competing risk of death and cardiac covariables was undertaken. RESULTS: Statin therapy was prescribed to 59% of the 478 included patients. The majority (88%) of patients not prescribed a statin had at least one indication for statin therapy according to cardiovascular guidelines. In total, 340 patients (71%) died and 79 patients (17%) experienced a cardiac event. High-intensity (HR 0.68, 95%CI 0.50-0.91, p = 0.012) and medium-intensity (HR 0.70, 95%CI 0.51-0.97, p = 0.033) statin therapy were associated with improved overall survival after adjustment for patient, cancer, treatment, response and cardiovascular clinical factors. There were no consistent differences in the rate or grade of cardiac events according to statin intensity. CONCLUSIONS: Statin therapy is associated with improved overall survival in patients receiving curative-intent radiotherapy for NSCLC, and there is evidence of a dose-response relationship. This study highlights the importance of a pre-treatment cardiovascular risk assessment in this cohort. Further studies are needed to examine if statin therapy is cardioprotective in patients undergoing treatment for NSCLC with considerable incidental cardiac radiation dose and a low baseline cardiac risk.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Walls GM, O'Connor J, Harbinson M, et al. Association between statin therapy dose intensity and radiation cardiotoxicity in non-small cell lung cancer: Results from the NI-HEART study. Radiother Oncol. 2023. PMID: 37348608. doi:10.1016/j.radonc.2023.109762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。